Updates
-
-
Eurordis Unveils Integrated-care Initiative for Rare Disease Patients
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their ... Read more -
Summit Fuels Discussion on New and Upcoming Hemophilia Treatments
For the second year, key pharmaceutical and academic leaders in hemophilia therapy development will gather at the Hemophilia Drug Development Summit — to be held ... Read more -
The Demands of a Job vs. the Need for Healthcare
I work as a pastor in the United Methodist Church. One of the many challenges of participating in a denomination that calls ministers to ... Read more -
Children Are Different, and So Are Their Experiences with Hemophilia
Most people will tell you that their children are opposites. One is outgoing, the other would rather be left alone. One will talk until ... Read more
-
Factor your way: empowering you to achieve your goals
What is hemophilia? Hemophilia is a rare genetic bleeding disorder that prevents blood from ... -
Hemlibra OK’d by Health Canada for Hemophilia A Patients Without Factor VIII Inhibitors
Health Canada has approved Hemlibra (emicizumab) for people with Hemophilia A without factor VIII ... -
Support Changes Everything
Hemophilia takes a toll not just on the life of the individual who struggles ... -
Practicing Self-care as a Mom and a Spouse to a Person with Hemophilia
It’s been nearly five months since I became a mom to baby Cittie. In ... -
High Adherence to Prophylaxis Improves Physical Activity of Patients With Hemophilia A, Study Says
High adherence to prophylactic treatment not only reduces the number of spontaneous bleeding episodes ...
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
Europe’s CHMP Recommends Approval of Hemlibra to Treat Hemophilia A
News
Europe’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the approval of Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in hemophilia A patients with factor VIII inhibitors. Hemlibra is a humanized monoclonal antibody that ... Read more